Advance Multicenter Clinical Trial: MRD-Driven Therapy in Newly Diagnosed Multiple Myeloma Patients

被引：0
|
作者：
Landgren, Ola [1 ]
Kazandjian, Dickran [2 ]
机构：
[1] Univ Miami, Sylvester Comprehens Canc Ctr, Myeloma Div, Miami, FL USA
[2] Univ Miami, Sylvester Comprehens Canc Ctr, Myeloma Div, Miami, FL USA
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-202079
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：7035 / 7036
页数：2
相关论文
共 50 条
  • [1] ADVANCE multicenter clinical trial: MRD-driven therapy in newly diagnosed multiple myeloma patients
    Landgren, Ola
    Maura, Francesco
    Kazandjian, Dickran
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S61 - S61
  • [2] Advance Multicenter Clinical Trial: MRD-Driven Therapy in Newly Diagnosed Multiple Myeloma Patients
    Landgren, Ola
    Maura, Francesco
    Kazandjian, Dickran
    BLOOD, 2023, 142
  • [3] MRD-driven treatment paradigm for newly diagnosed transplant eligible multiple myeloma patients
    O Landgren
    S Giralt
    Bone Marrow Transplantation, 2016, 51 : 913 - 914
  • [4] MRD-driven treatment paradigm for newly diagnosed transplant eligible multiple myeloma patients
    Landgren, O.
    Giralt, S.
    BONE MARROW TRANSPLANTATION, 2016, 51 (07) : 913 - 914
  • [5] MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma
    Bhutani, Manisha
    Robinson, Myra
    Foureau, David
    Atrash, Shebli
    Paul, Barry
    Guo, Fei
    Grayson, Jason M.
    Ivanina-Foureau, Anna
    Pineda-Roman, Mauricio
    Varga, Cindy
    Friend, Reed
    Ferreri, Christopher J.
    Begic, Xhevahire
    Norek, Sarah
    Drennan, Tiffany
    Anderson, Michelle B.
    Symanowski, James T.
    Voorhees, Peter M.
    Usmani, Saad Z.
    BLOOD ADVANCES, 2025, 9 (03) : 507 - 519
  • [6] Predictors and MRD-Driven Treatment Strategies of Unsustained Measurable Residual Disease Negativity in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma
    Li, Xiaozhe
    Li, Juan
    BLOOD, 2024, 144 : 4710 - 4710
  • [7] Implications of isolated MRD progression in newly diagnosed multiple myeloma treated with quadruplet therapy
    Costa, Luciano J.
    Medvedova, Eva
    Dhakal, Binod
    Dholaria, Bhagirathbhai R.
    Godby, Kelly N.
    Bal, Susan
    Ravi, Gayathri
    Giri, Smith
    Chhabra, Saurabh
    Silbermann, Rebecca
    Callander, Natalie S.
    BLOOD CANCER JOURNAL, 2025, 15 (01):
  • [8] Frontline therapy for newly diagnosed patients with multiple myeloma
    Jung, Sung-Hoon
    Jo, Jae-Cheol
    Song, Ga-Young
    Ahn, Seo-Yeon
    Yang, Deok-Hwan
    Ahn, Jae-Sook
    Kim, Hyeoung-Joon
    Lee, Je-Jung
    BLOOD RESEARCH, 2020, 55 : 37 - 42
  • [9] RADAR Trial: MRD Response Adapted Trial for Newly Diagnosed Transplant Eligible Myeloma Patients
    Ramasamy, Karthik
    Cairns, David Allan
    Royle, Kara-Louise
    Cicero, Robert
    Olivier, Catherine
    Barnard, Lorna
    Jackson, Sharon
    Levinte, Doina
    Cook, Gordon
    Chant, Alan
    Meads, David
    Dawkins, Bryony
    Chapman, Michael A.
    Pratt, Guy
    Popat, Rakesh
    Jackson, Graham
    Bygrave, Ceri
    Chantry, Andrew
    Kaiser, Martin F.
    Sive, Jonathan
    Parrish, Christopher
    Smith, Dean
    Jenner, Matthew W.
    Drayson, Mark
    Owen, Roger
    de Tute, Ruth M.
    Mehta, Dipal
    Yong, Kwee
    BLOOD, 2023, 142
  • [10] Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis
    O Landgren
    S Devlin
    M Boulad
    S Mailankody
    Bone Marrow Transplantation, 2016, 51 : 1565 - 1568
12345